Affymetrix, Inc.  

(Public, NASDAQ:AFFX)   Watch this stock  
Find more results for AFFX
3.67
-0.01 (-0.27%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.66 - 3.74
52 week 2.96 - 5.50
Open 3.68
Vol / Avg. 376,126.00/644,992.00
Mkt cap 260.93M
P/E     -
Div/yield     -
EPS -0.32
Shares 71.10M
Beta 2.17
Inst. own 104%
Jul 29, 2013
Q2 2013 Affymetrix Earnings Release Add to calendar
May 14, 2013
Affymetrix at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Affymetrix Annual Shareholder Meeting
Apr 30, 2013
Q1 2013 Affymetrix Earnings Conference Call - Webcast
Apr 29, 2013
Q1 2013 Affymetrix Earnings Release
Mar 6, 2013
Affymetrix at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -19.80% -3.62%
Operating margin -15.66% -13.22%
EBITD margin - 3.39%
Return on average assets -11.53% -2.18%
Return on average equity -23.00% -3.88%
Employees 1,100 -
Carbon Disclosure Rating - -

Address

3420 Central Expressway
SANTA CLARA, CA 95051
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
Discussion Group - Google Finance

Description

Affymetrix, Inc. (Affymetrix) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. Affymetrix has developed its GeneChip system and related microarray technology as a platform for acquiring, analyzing and managing genetic information. The Company offers a line of products for two principal applications: genotyping and gene expression. Related microarray technology also offered by Affymetrix includes licenses for fabricating, scanning, collecting and analyzing results from complementary technologies. The Company sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies, as well as academic research centers, government research laboratories, private foundation laboratories and clinical reference laboratories in North America and Europe. In June 2012, the Company acquired eBioscience Holding Company, Inc.

Officers and directors

Stephen P. A. Fodor Ph.D. Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Frank Witney Ph.D. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Gavin Wood Chief Financial Officer, Executive Vice President
Age: 43
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Executive Vice President - Genetic Analysis Business Unit
Age: 53
Bio & Compensation  - Reuters
David Weber Executive Vice President - Global Commercial Operations
Age: 59
Bio & Compensation  - Reuters
Siang Chin General Counsel, Secretary
Bio & Compensation  - Reuters
Robert P. Wayman Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Nelson C. Chan Independent Director
Age: 51
Bio & Compensation  - Reuters
Gary S. Guthart Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Jami Dover Nachtsheim Independent Director
Age: 54
Bio & Compensation  - Reuters